Insulin resistance in polycystic ovary syndrome;Die insulinresistenz beim polyzystischen ovar-syndrom

Wiener Klinische Wochenschrift

Volumn 115, Issue 23, 2003, Pages 812-821

  Schröder, Annika K ^a   Tauchert, Sascha ^a   Ortmann, Olaf ^b   Diedrich, Klaus ^a   Weiss, Jürgen M ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Cardiovascular risk; Diabetes mellitus; Insulin resistance; PCOS; Polycystic ovary syndrome; Risks

Indexed keywords

ANTIANDROGEN; CLOMIFENE CITRATE; CYPROTERONE ACETATE; ETHINYLESTRADIOL; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ADULT; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREGNANCY DIABETES MELLITUS; REVIEW; RISK FACTOR; SCREENING TEST; SPONTANEOUS ABORTION;

EID: 0347764694     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03041041     Document Type: Review

References (87)

1. Achard C, Thiers J (1921) Le virilisme pilaire et son association a l'insuffisance glycolytique (diabete des femmes a barbe). Bull Acad Natl Med 86: 51-64
2. Amowitz LL, Sobel BE (1999) Cardiovascular consequences of polycystic ovary sysdrome. Endocrinol Metab Clin North Am 28: 439-458
3. Arslanian SA, Lewy VD, Danadian K (2001) Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insuline resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 86: 66-71
4. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T (2002) Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 54: 94-98
5. Björntorp P (1996) The android women - a risky condition. J Intern Med 239: 105-110
6. Book C-B, Dunaif A (1999) Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 84: 3110-3116
7. Buchanan TA, Xiang AH, Peters RK, et al (2001) Protection from type 2 diabetes persists in the TRIPOD cohort 8 months after stopping troglitazone. Diabetes Care 50: A81
8. Burghen GA, Givens JR, Kitabchi AE (1983) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian syndrome. J Clin Endocrinol Metab 50: 133
9. Carmina E, Lobo RA (2001) Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84: 1897-1899
10. Cataldo NA, Abbasi F, McLaughlinn TL, Lamendola C, Reaven GM (2001) Improvement in insulin sensitivity followed by ovulation and pregnancy in a women with polycystiv ovary syndrome who was treated with rosiglitazone. Fertil Steril 76: 1057-1059
11. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS (1997) Treatment with the oral antidiabetic agent troglitazone improves beta cell response to glucose in subjects with impaired glucose tolerance. J Clin Invest 100: 530-537
12. Cibula D, Skrha J, Hill M, et al (2002) Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 5821-5825
13. Coetzee EJ, Jackson WP (1979) Metformin in management of pregnant insulin-independent diabetes. Diabetologica 16: 241-245
14. Colilla S, Cox NJ, Ehrmann DA (2001) Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 86: 2027-2031
15. Conn JJ, Jacobs HS, Conway GS (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52: 81-86
16. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS (1992) Risk factors for coronary artery disease in lean and obese women with the poycystic ovary syndrome. Clin Endocrinol (Oxf) 37: 119-125
17. Dahlgren E, Janson PO, Johannsson S, Lapidus L, den A (1992) Polycystic ovary syndrome and risk for myocardial infarction. Evaluation from a risk factor model based on a prospective population based study of women. Acta Obstet Gynecol Scand 71: 599-603
18. Diamanti-Kandarakis E, Baillargeon J-P, Iurno MJ, Jakubowicz DJ, Nestler JE (2003) A modern medical quandary: polycystic ovary syndrome, insulin resistance and oral contraceptive pills. J Clin Endocrinol Metab 88: 1927-1932
19. Diamanti-Kandarakis E, Mitrakou A, Hennes MMI, et al (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 44: 525-531
20. Diamanti-Kandarakis E, Spina G, Kouli CM, I (2001) Increased endothelin-1 levels in owmen with polycystiv ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86: 4666-4673
21. Dunaif A (1992) Insulin resistance and ovarian hyperandrogenism. Endocrinologist 2: 248-260
22. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774-800
23. Dunaif A, Finegood DT (1996) β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 942-947
24. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A (1987) Characterization of groups of hyperandorgenemic women with acanthosis nigricans, impaired glucose tolerace, and/or hyperinsulinemia. J Clin Endocrinol Metab 65: 499-507
25. Dunaif A, Green G, Futterweit W, Dobrjansky A (1990) Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70: 699-704
26. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound periperal insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174
27. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A (1992) Evidence of distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41: 1257-1266
28. Dunaif A, Xia J, Book C-B, Schenker E, Tang Z (1995) Excessiv insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. J Clin Invest 96: 801-810
29. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystiv ovary syndrome. Diabetes Care 22: 141-146
30. Ehrmann DA, Scheider DJ, Sobel BE, Cavaghan MK, Imperial J, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis inwomen with polycystic ovary sydrome. J Clin Endocrinol Metab 82: 2108-2116
31. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS (1995) Insulin secretory defects in polycystic ovary sydrome. J Clin Invest 96: 520-527
32. Erickson GF, Magoffin DA, Cragun JF, Chang RJ (1990) The effects of insulin and insulin-like growth factors-I and II onestradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab 70: 894-902
33. Fox JH, Licholai T, Green G, Dunaif A (1993) Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgem levels in women. Fertil Steril 60: 994-1000
34. Franks S, Gharani N, McCarthy M (1993) Candidate geses in polycystic ovary syndrome. Hum Reprod Update 200147: 405-410
35. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW (2003) Effecto of rosiglitazone on spontanous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79: 562-566
36. Glueck CJ, Wang P, Goldberg N, Sieve-Smith L (2002) Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17: 2858-2864
37. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L (2002) Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77: 520-525
38. Harris MI, Hadden WC, Knowler WC, Bennett PH (1987) Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36: 534
39. Holte J, Gennarelli G, Wilde L, Lithell H, Berne C (1998) High prevalence of polycystic ovaries and associated clinical, endorcine and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 83: 1143-1150
40. Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25: 2244-2248
41. Kannel WB, D'Agostino RB, WIlson PW, Belanger AJ, Gagnon DR (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120: 672-676
42. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 86: 2453-2455
43. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary sydrome. Clin Endocrinol (Oxf) 36: 105-111
44. King H, Rewers M (1993) Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 16: 157-177
45. Knowler WC, Barrett-Connor E, Fowler SE, et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-303
46. Kousta E, Cela E, Lawrence N, et al (2000) The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf) 53: 501-507
47. Lanzone A, Caruso A, DiSimone N, DeCarolis S, Fulghesu AM, Mancuso S (1995) Polycystic ovary disease. A risk factor for gestational diabetes? J Reprod Med 40: 312-316
48. Legro RS, Finegood DT, Dunaif A (1998) A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystiv ovary syndrome. J Clin Endocrinol Metab 83: 2694-2698
49. Legro RS, Kunselmann AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165-169
50. Legro RS, Kunselmann AR, Dunaif A (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovariey syndrome. Am J Med 111: 607-613
51. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A (2001) Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 16: 226-229
52. Modan M, Harris MI, Halkin H (1989) Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes 38: 1603-1635
53. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SSC (1996) Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct figures. J Clin Endocrinol Metab 81: 2854-2864
54. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ (2003) Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 812-819
55. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen H (1998) Metformin therapy improves the mentrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69: 691-696
56. Nahum R, Thong KJ, Hillier SG (1995) Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod 10: 75-81
57. Nestler JE, Jakubowicz DJ (1996) Decreases inovarian cytochrome P450C17-activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335: 617-623
58. Nestler JE, Jakubowicz DJ, Reamer P, Gunn R, Allan G (1999) Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340: 1314-1320
59. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ (2001) Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16: 1995-1998
60. O'Meara M, Blackman JD, Ehrmann DA (1996) Defects in b-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76: 1241-1247
61. O'Meara M, Blackman JD, Ehrmann DA, et al (1993) Defects in beta-cell function in functional ovarian hyperandrogensm. J Clin Endocrinol Metab 76: 1241-1247
62. Ovesen P, Moeller J, Ingerslev HJ, et al (1993) Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 77: 1636-1640
63. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 1017-1023
64. Paradisi G, Steinberg HO, Hemofling A, et al (2001) Polycystic ovary syndrome is associated wtih endothelial dysfunction. Circulation 103: 1410-1415
65. Peppard HR, Marfori J, Iurno MJ, Nestler JE (2001) Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24: 1050-1052
66. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51: 581-586
67. Poretsky L, Kalin MF (1987) The gonadotropic function of insulin. Endocr Rev 8: 132-141
68. Randeva HS, Lewandowski KC, Drzewoski J, et al (2002) Exercise decreases plasma total homocystein in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 4496-4501
69. Salobir B, Prezelj J, Kocijancic A, Meden-Vrotovec H (2002) Basal glucose level as an independent predictor of fertilization rate in patients without polycystic ovary syndrome included in an in-vitro fertilization program. Wien Klin Wochenschr 114: 454-457
70. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R (2003) Insuin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocystein. Hum Reprod 18: 721-727
71. Shobokshi A, Shaarawy M (2003) Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphen citrate therapy. J Soc Gynecol Invest 10: 99-104
72. Solomon CG, Hu FB, Dunaif A, et al (2001) Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87: 2013-2017
73. Solomon CG, Hu FB, Dunaif A, et al (2001) Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 286: 2421-2426
74. Talbott E, Clerici A, Berga S, et al (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystiv ovary syndrome: results of a case-control study. J Clin Epidemiol 51: 415-422
75. Talbott E, Guzick D, Clerici A, et al (1995) Conorary disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15: 821-826
76. Talbott E, Guzick D, Sutton-Tyrrell K, et al (2000) Evidence of associaton between polycystic ovary syndrome and premature carotid atherpsclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20: 2414-2421
77. The National Cholesterol Education Program (NCEP) Expert Panel (2001) Executive summary of the third report of the national cholsterol education program (NCEP) expert panal on the detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 285: 2486-2497
78. Tuomilehto J, Lindstrom J, Eriksson JG, et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1347
79. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensice blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865
80. Van Dam EW, Roelfsema F, Veldhuis JD, et al (2002) Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. Am J Physiol Endocrinol Metab 282: E865-872
81. Velazquez EM, Mendoza R, Hamer T, Sosa F, Glueck CJ (1994) Metformin therapy in polycystiv ovary syndrome reduces hyperinsulinemia, imsulin resistance, hyperandrogenemia and systolic blood pressure while facilitation normal menses and pregnancy. Metabolism 43: 647-654
82. Velazquez EM, Mendoza SG, Wang P, Glueck CJ (1997) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a) and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 46: 454-457
83. Wild RA (1995) Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 98: 27S-32S
84. Wild RA, Alaupovic P, Parker IJ (1992) Lipid and apolipoprotein abnormalities in hirusite women. Am J Obstet Gynecol 166: 1191-1197
85. Wild S, Pierpoint T, McKeigue PM, Jacobs HS (2000) Cardiovascular disease in women with polycystic syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52: 595-600
86. Wortsman J, de Anfeles S, Futterweit W, Singh KB, Kaufmann RC (1991) Gestational diabetes and neonatal amrosomia in the polycystic ovary syndrome. J Reprod Med 36: 659-661
87. Xia YX, Weiss JM, Polack S, Diedrich K, Ortmann O (2001) Interactions of insulin-like growth factor-I, insulin and estradiol with GnRh-stimulated luteinizing hormone release from female rat gonadotrophs. Eur J Endocrinol 144: 73-79